(ONC-DPX-Survivac-06): A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer
Phase 2 of this clinical trial evaluates the safety and effectiveness of an investigational cancer vaccine, DPX-Survivac, plus low-dose oral cyclophosphamide in women with proven recurrent ovarian cancer.
Fallopian tube cancer
Primary peritoneal cancer
1. Confirmed diagnosis of Stage IIc-IV epithelial ovarian, fallopian tube, or peritoneal cancer and completion of first-line treatment.
2. Evidence of progressive disease-- either by rising CA-125 and/or radiologic imaging-- at least 3 months after completion of first-line platinum-based chemotherapy (other therapies after first-line are allowed).
3. Must be willing to have a pre-treatment tumor biopsy performed, and be willing to undergo tumor biopsy during treatment as well.
4. Other criteria will apply
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participation can continue for one year, or until subjects experience disease progression or develop intolerable side effects, whichever occurs first. After participation ends, subjects will be followed every 6 months for 5 years.
Yukie Tarumi Bean, CCRP
Gyn/Onc Study Coordinator
ImmunoVaccine Technologies Inc. (IMV, Inc.)